C) Graphical analysis of the Western blot in (B)

C) Graphical analysis of the Western blot in (B). longitudinally in response to tumor antigens in living mice. This methodology has the potential to Bz 423 accelerate the study of adoptive immunotherapy in preclinical Bz 423 cancer models. Keywords:Bioluminescence imaging, Granzyme B, T-cell activation, Two step transcriptional amplification (TSTA), CMV enhancer == Introduction == Cellular immunity plays a key role in immunosurveillance of early cancers, prevention of relapse from minimal residual disease, and these roles are being exploited in the design of cancer vaccines (1) and adoptive immune cell therapies (2-4). To achieve full therapeutic potential for adoptively transferred Bz 423 T-cells, large numbers need to be injected into patients (5,6). Current culture techniques needed to reach these numbers can cause negative effects on the functional characteristics of the modified T-cells, making them less effective in Bz 423 patients (5). Therefore, it is important to monitor the function of cytotoxic and/or helper T-cells prior to and after adoptive transfer. Currently, cytotoxic T-cell function is usually measured through cell killing assays on target cells, whereas helper T-cells are analyzed for their cytokine production during exposure to target antigens. In living subjects, however, T-cell function is usually measured by therapeutic outcome (e.g., reduction in tumor volume). While tumor-specific T-cells may have great efficacy in CTL assays, they are often ineffective against target tumor cells when injected in living subjects (reviewed in(7)). Research into the cell culture conditions and re-targeting EFNA1 of T-cells using chimeric T-cell receptors has improved the efficacy of tumor-specific T-cells in living subjects. Recently Morgan et al.(8) found partial success in treating melanoma patients using re-targeted T-cells partly due to culturing retargeted T-cells for less than a week. Various strategies for improving the efficacy of immunoadoptive therapy such as modifications of cell culture conditions, alterations in T-cell repertoire, and identifying the cell population(s) responsible for tumor eradication would greatly benefit from an imaging tool to non-invasively visualize the function of transferred T-cells in living subjects. In this study, we pursued this goal by linking the promoters of T-cell activation markers to reporter genes commonly employed for molecular imaging. Markers of T-cell activation such as interleukin-2 (IL-2) and Granzyme B are routinely used to gauge the activation status of T-cells in cell culture andex vivo(9). The cytokine IL-2 is usually produced mainly by CD4+T-cells in the early stages of activation. In contrast, the expression of Granzyme B in CD8+T-cells signifies their full differentiation and acquisition of killing potential (10). The full-length Granzyme B promoter (~9kb) has been well characterized and contains in its distal end binding sites for the AP-1, CBF, and CRE transcription factors (11,12) which are induced during T-cell activation (13) and can drive reporter gene expression during T-cell activation at a level sufficient forin vitrodetection (12). By coupling this promoter to a bioluminescence reporter gene, we inferred that CTL function could be visualized in live small animals. However, our initial experiments showed the bioluminescence signal generated by this promoter to be too weak for detection in living animals. Detection of reporter gene expression from tissue-specific promoters can indeed be difficult in living animals such as mice and rats (14,15). Several methods have been reported to increase promoter activity in order to enhance the production of reporter or therapeutic proteins– these include multimerizing promoters, using full length promoters, creating hybrid promoters, and using two step systems based on the yeast two hybrid system (14,16). Hybrid promoters that use the CMV enhancer (CMVe), a strong transcriptional enhancer, in conjunction with the tissue-specific promoter (17,18) and the Two Step Transcription Amplification strategy (TSTA) (seeSupplementary Fig. S1online) (14) have.